Howe & Rusling Inc. bought a new stake in shares of Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 440 shares of the company’s stock, valued at approximately $31,000.
Several other hedge funds have also recently modified their holdings of PBE. Ashton Thomas Private Wealth LLC purchased a new stake in Invesco Biotechnology & Genome ETF during the second quarter worth $26,000. GPS Wealth Strategies Group LLC purchased a new stake in shares of Invesco Biotechnology & Genome ETF during the second quarter valued at about $30,000. UMB Bank n.a. purchased a new position in shares of Invesco Biotechnology & Genome ETF in the 2nd quarter worth approximately $31,000. Covestor Ltd raised its stake in shares of Invesco Biotechnology & Genome ETF by 24.2% during the 1st quarter. Covestor Ltd now owns 955 shares of the company’s stock worth $62,000 after acquiring an additional 186 shares in the last quarter. Finally, Carnegie Investment Counsel purchased a new stake in Invesco Biotechnology & Genome ETF during the third quarter valued at approximately $204,000.
Invesco Biotechnology & Genome ETF Trading Up 1.6 %
NYSEARCA PBE opened at $67.64 on Thursday. The firm’s fifty day simple moving average is $69.37 and its two-hundred day simple moving average is $67.76. The firm has a market capitalization of $273.27 million, a P/E ratio of 17.12 and a beta of 0.88. Invesco Biotechnology & Genome ETF has a 12-month low of $56.21 and a 12-month high of $72.84.
About Invesco Biotechnology & Genome ETF
PowerShares Dynamic Biotechnology & Genome Portfolio (the Fund) is based on the Dynamic Biotechnology & Genome Intellidex Index (the Index). The Fund seeks investment results that correspond generally to the price and yield of the Index. The Index consists of stocks of 30 the United States biotechnology and genome companies.
Read More
- Five stocks we like better than Invesco Biotechnology & Genome ETF
- 3 Tickers Leading a Meme Stock Revival
- Target Results Are Not a Retail Bellwether: Why the Dip Is a Buy
- 3 Stocks to Consider Buying in October
- Williams-Sonoma Stock: Buy It and Never Let It Go
- How to Invest in Insurance Companies: A Guide
- 5 Dividend ETFs to Buy and Hold Forever
Want to see what other hedge funds are holding PBE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invesco Biotechnology & Genome ETF (NYSEARCA:PBE – Free Report).
Receive News & Ratings for Invesco Biotechnology & Genome ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invesco Biotechnology & Genome ETF and related companies with MarketBeat.com's FREE daily email newsletter.
